Trial Profile
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Dec 2023
Price :
$35
*
At a glance
- Drugs Solanezumab (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms A4
- Sponsors Eli Lilly and Company
- 01 Oct 2023 Status changed from active, no longer recruiting to completed.
- 20 Jul 2023 Results presented at the Alzheimer's Association International Conference 2023
- 20 Jul 2023 Results (n=1641) assessing Functional connectivity of the frontoparietal control network is positively associated with cognition, independent of amyloid and tau burden presented at the Alzheimer's Association International Conference 2023